 MIRAMAR, Fla., Dec. 31, 2020 GLOBE NEWSWIRE -- Generex Biotechnology Corporation OTCQB:GNBT today announced that its majority owned public entity, NuGenerex Immuno-Oncology, Inc. NGIO, has filed for and expects to receive a trademark for The Complete VaccineTM. A complete vaccine is designed to regulate the immune system to provide a targeted, neutralizing antibody response without generating off-target, non-neutralizing antibodies that can lead to antibody dependent enhancement of disease ADE; further a complete vaccine should activate the appropriate T cell responses to yield long-term immune memory without activating detrimental Th2 responses that have been associated with immune-related complications of COVID-19 disease. 